T3 N1 M0 rectal cancer: optimal initial management is total neoadjuvant therapy

被引：0
作者：
Nilsson, Per J. [1 ,2 ]
机构：
[1] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[2] Karolinska Inst, Dept Mol Med & Surg, Euegeniav 6, Hotellet pl 2, SE-17176 Stockholm, Sweden
来源：
BRITISH JOURNAL OF SURGERY | 2024年 / 111卷 / 01期
关键词：
PREOPERATIVE CHEMORADIOTHERAPY; OPEN-LABEL; CHEMOTHERAPY;
D O I：
10.1093/bjs/znad322
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [31] What is the optimal adjuvant therapy for T3N0 lung cancer invading the chest wall?
    Suzuki, Makoto
    Mori, Takeshi
    Shiraishi, Kenji
    Ikeda, Koei
    Masuda, Yoshiko
    Matsubara, Eri
    Shirakami, Chika
    Hinokuma, Hironori
    JOURNAL OF THORACIC DISEASE, 2017, 9 (11) : 4233 - 4235
  • [32] Towards personalized treatment of T2N0 rectal cancer: A systematic review of long-term oncological outcomes of neoadjuvant therapy followed by local excision
    Peltrini, Roberto
    Imperatore, Nicola
    Di Nuzzo, Maria Michela
    Pellino, Gianluca
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (08) : 1426 - 1433
  • [33] Does T1c-2N0-1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
    Chen, Ruiliang
    Yu, Yushuai
    Chen, Weiwei
    Fu, Wenfen
    Song, Chuangui
    Zhang, Jie
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01) : 599
  • [34] Outcomes of trimodality approach in the management of T2N0M0 bladder cancer
    Uysal, Bora
    Beyzadeoglu, Murat
    Demiral, Selcuk
    Gamsiz, Hakan
    Dincoglan, Ferrat
    Sager, Omer
    Akin, Mustafa
    Babayigit, Mustafa Alparslan
    TUMORI, 2015, 101 (02) : 232 - 237
  • [35] Differences in risk factors for mortality between T2N1M0 and T3N0M0 lobular breast cancer patients: a comparative study
    Xia, Longjie
    Qin, Chunxin
    Chen, Wei
    Chen, Kang
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [36] Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers
    Lavryk, Olga A.
    Manilich, Elena
    Valente, Michael A.
    Miriam, Arshiya
    Gorgun, Emre
    Kalady, Matthew F.
    Shawki, Sherief
    Delaney, Conor P.
    Steele, Scott R.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (01) : 77 - 84
  • [37] Residual Nodal Disease in Biopsy Proven N1/N2 Breast Cancer Following Neoadjuvant Systemic Therapy
    Al Mushawah, Fatema
    Tan, Marcus C.
    Margenthaler, Julie A.
    WORLD JOURNAL OF SURGERY, 2010, 34 (02) : 256 - 260
  • [38] Adjuvant therapy for pathological T3N0M0 esophageal squamous cell carcinoma
    Zhang, Xiaobin
    Yang, Yu
    Sun, Yifeng
    Ye, Bo
    Guo, Xufeng
    Mao, Teng
    Hua, Rong
    Li, Bin
    Gu, Haiyong
    Liu, Jun
    Li, Zhigang
    JOURNAL OF THORACIC DISEASE, 2019, 11 (06) : 2512 - 2522
  • [39] A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer
    Foroughi, Freshte
    Javadinia, Seyed Alireza
    Salek, Roham
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] Induction therapy for clinical stage T2N0M0 esophageal cancer A systematic review and meta-analysis
    Lv, Hong-Wei
    Xing, Wen-Qun
    Shen, Si-Ning
    Cheng, Ji-Wei
    MEDICINE, 2018, 97 (40)
12345